RT @IHSMarkit: "If you want to take care of shareholders, you better take care of your people, and you better take care of your planet, and…
IHS Healthcare and Pharma is now IHS Life Sciences
The IHS Healthcare and Pharma team is happy to announce that we are now IHS Life Sciences. Our new group name better conveys the breadth and depth of our products and services, the companies we work with, and the industries we serve.
Combining our deep knowledge of the industry - integrated access to Pricing and Reimbursement expertise, healthcare economic modeling, and pharmaceutical competitive intelligence - with the extensive economic and analytical capabilities of IHS - technology, supply chain, operational excellence, and modeling - we are able to bring together insights that truly help you, our readers and our clients, work better, smarter, and more profitably.
As of today, you will see our new name here on our blog, on our website www.ihs.com/LifeSciences, and our new twitter handle @IHS4LifeScience.
Thank you for continuing to read our blog and share what you learn with us. We hope you will join us at ISPOR in Montreal this May and in Amsterdam in November to celebrate our new name. We will share details with you as the dates get closer.
- The race intensifies for a COVID-19 vaccine as hope builds for emergency approval by September
- Is the US ready to start relaxing COVID-19 lockdowns?
- COVID-19 could cause delays for price framework agreements in parts of Europe
- US scrambles for resources in COVID-19 response
- COVID-19: Risk of severe complications among the United States health workforce
- COVID-19 pandemic: Health system surge capacity
- UK bans parallel export of two COVID-19 treatment candidates to protect national supply
- China’s young biosimilars sector
RELATED INDUSTRIES & TOPICS
The race intensifies for a COVID-19 vaccine as hope builds for emergency approval by September https://t.co/9fX4R1K8rC